Frontage Laboratories, Inc. and Telomir Pharmaceuticals, Inc. present Promising Pre-clinical Data for Telomir’s Lead Development Product
Frontage Laboratories, Inc. (“Frontage”) and Telomir Pharmaceuticals, Inc. (“Telomir”) recently presented promising pre-clinical data for Telomir‘s lead development product at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024.
The data highlighted the effect of Telomir-1 on telomere length in three human cell lines: MRC-5 fetal lung fibroblasts, human umbilical endothelial cells (HUVEC), and mesenchymal stem cells (MSC).
Danielle R. Baker, Ph.D., of Frontage, presented the poster, titled “Telomir-1 Induces Telomere Extensions in Primary Human Cell Strains,” at the conference, which took place in Singapore, on February 29th and March 1st. The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.
“We are honored that this poster was accepted for presentation at the NUHS Conference. Moreover, the promising data we presented at the NUHS Conference showed the advances we are making at potentially treating age-related conditions and prolonging human life,” stated Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir. “If Telomir-1 can safely extend telomeres in people, it could vastly alter the aging process and redefine our potential for living longer, healthier lives. We are excited at what the future holds and we look forward to presenting additional data to the longevity community in the coming months.”
For more information on the partnership and presentation, click here.
